Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 11;9(9):927. doi: 10.1038/s41419-018-0905-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Annexin V/ 7AAD apoptosis analysis of K562 cells treated with IM, BMP inhibitors and the combination (IM = 500 nM, LDN = 500 nM, DOR = 2.5 μM, n = 3) at 72 h. i Inhibition of BCR-ABL and BMP pathway results in apoptosis, and a reduction in viable cells. ii Results are significantly more profound when IM is used in combination with DOR with more cells in early apoptosis (n = 3). b Annexin V/7AAD apoptosis analysis of normal and CP-CML CD34⁺ cells treated with IM, BMP inhibitors and the combination (IM = 1 µM, LDN = 1 µM, DOR = 2.5 μM, n = 3) at 72 h. i, ii Results indicate that IM in combination with BMP pathway inhibitors promote modest, but significant, apoptosis in normal CD34 + cells. However, apoptosis is greatly increased in CP-CML CD34⁺ samples. This is reflected in the increased number of cells present in late apoptosis (n = 3). iii, iv Inhibitor treatments with addition of BMP4 also indicate a significant increase of normal and CP-CML CD34⁺ cells in late apoptosis, with more apoptosis observed in the CML CD34⁺ samples (n = 3)